SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis
Epidemiological studies of the COVID-19 pandemic have revealed evidence of cardiac involvement and documented that myocardial injury and myocarditis are predictors of poor outcomes. Nonetheless, little is understood regarding SARS-CoV-2 tropism within the heart and whether cardiac complications resu...
Saved in:
Published in | bioRxiv |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article Paper |
Language | English |
Published |
United States
Cold Spring Harbor Laboratory Press
05.11.2020
Cold Spring Harbor Laboratory |
Edition | 1.1 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Epidemiological studies of the COVID-19 pandemic have revealed evidence of cardiac involvement and documented that myocardial injury and myocarditis are predictors of poor outcomes. Nonetheless, little is understood regarding SARS-CoV-2 tropism within the heart and whether cardiac complications result directly from myocardial infection. Here, we develop a human engineered heart tissue model and demonstrate that SARS-CoV-2 selectively infects cardiomyocytes. Viral infection is dependent on expression of angiotensin-I converting enzyme 2 (ACE2) and endosomal cysteine proteases, suggesting an endosomal mechanism of cell entry. After infection with SARS-CoV-2, engineered tissues display typical features of myocarditis, including cardiomyocyte cell death, impaired cardiac contractility, and innate immune cell activation. Consistent with these findings, autopsy tissue obtained from individuals with COVID-19 myocarditis demonstrated cardiomyocyte infection, cell death, and macrophage-predominate immune cell infiltrate. These findings establish human cardiomyocyte tropism for SARS-CoV-2 and provide an experimental platform for interrogating and mitigating cardiac complications of COVID-19. |
---|---|
Bibliography: | SourceType-Working Papers-1 ObjectType-Working Paper/Pre-Print-1 content type line 50 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 Competing Interest Statement: Kory Lavine - Medtronic: DT-PAS/APOGEE trial advisory board. M.S.D. is a consultant for Inbios, Eli Lilly, Vir Biotechnology, NGM Biopharmaceuticals, and on the Scientific Advisory Board of Moderna. The Lavine laboratory has received funding and unrelated sponsored research agreements from Amgen. The Diamond laboratory has received funding and unrelated sponsored research agreements from Moderna, Vir Biotechnology, and Emergent BioSolutions. Lina Greenberg, W. Tom Stump, Michael Greenberg, Adam Bailey, Oleksandr Dmytrenko, Andrea Bredemeyer - None. |
ISSN: | 2692-8205 2692-8205 |
DOI: | 10.1101/2020.11.04.364315 |